Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Background All randomised phase 3 studies of selective internal radiation therapy for
advanced hepatocellular carcinoma published to date have reported negative results …

Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Background Sorafenib is the recommended treatment for patients with advanced
hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that …

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in
unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the …

Recent advances in systemic and locoregional treatments for patients with unresectable or
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …